Assyro AI

FDA Orange Book · active-ingredient family

Ziprasidone hydrochloride

Ziprasidone hydrochloride is approved as 2 brand and 9 generic applications in the FDA Orange Book, with their therapeutic-equivalence codes, listed patents, and marketing exclusivity.

Reference-listed drug:GEODON · NDA 020825

2

Brand (NDA)

9

Generics (ANDA)

0

Listed patents

0

Exclusivity periods

Brand (NDA) products · capsule, suspension

ProductApplicantApplicationTEApproved
GEODONRLD×4VIATRISNDA 020825ABFeb 05, 2001
GEODONPFIZER INCNDA 021483Mar 29, 2006

Generic (ANDA) products (9)

ProductApplicantApplicationTEApproved
ZIPRASIDONE HYDROCHLORIDE×4ZYDUS LIFESCIENCESANDA 208988ABAug 22, 2017
ZIPRASIDONE HYDROCHLORIDE×4MACLEODS PHARMS LTDANDA 204375ABFeb 17, 2017
ZIPRASIDONE HYDROCHLORIDE×4AUROBINDO PHARMAANDA 204117ABDec 27, 2016
ZIPRASIDONE HYDROCHLORIDE×4MYLANANDA 202395Oct 10, 2013
ZIPRASIDONE HYDROCHLORIDE×4CHARTWELL RXANDA 090348ABSep 05, 2012
ZIPRASIDONE HYDROCHLORIDE×4SANDOZ INCANDA 077562ABJun 01, 2012
ZIPRASIDONE HYDROCHLORIDE×4APOTEXANDA 077561ABMar 02, 2012
ZIPRASIDONE HYDROCHLORIDE×4DR REDDYS LABS INCANDA 077565ABMar 02, 2012
ZIPRASIDONE HYDROCHLORIDE×4LUPIN PHARMSANDA 077560Mar 02, 2012

Listed patents

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Ziprasidone hydrochloride — frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.